Insider Purchases: Inside the Buy
Tag: InsiderBuying
💳 Fiserv Insiders Keep Averaging Down. Wall Street Sees Trouble. Bulls See A 6x Earnings Cash Machine.
Fiserv's executives are putting their money where their mouths are. With insider buying surging, Clover processing $324 billion annually, and valuation multiples near historic lows, the payments giant has become one of Wall Street's more fascinating turnarounds.
🛵 The Local Commerce Media Machine: Auditing DoorDash's $100M Insider Moat and the 33% Top-Line AI Acceleration
DoorDash may be building something much larger than a delivery app. With 33% revenue growth, improving profitability, a $100 million insider purchase, and potential AI commerce advantages, DASH remains one of the most fascinating platform stories in tech.
🏝️ The 125% Float Monopoly: Inside Oxford Industries' High-Conviction Floor and the 8-Day Island Squeeze
With insiders buying, institutions owning more than the float itself, a 7.5% dividend yield and Tommy Bahama still thriving, Oxford Industries presents one of the more unusual setups in retail.
🧠 Cognizant (CTSH): The Impossible Float Monopoly, Project Leap, and a 9x Multiple GARP Arbitrage
Cognizant may be one of the market's most overlooked AI transformation stories. Strong bookings, aggressive buybacks, and a surprisingly cheap valuation suggest investors may be pricing the company too pessimistically.
🧗 VF Corporation (VFC): The North Face Pivot, a 92% Institutional Grip, and the 0.40 PEG Ratio Turnaround
After falling more than 80% from its peak, VF Corporation is quietly rebuilding. Insider buying, strong free cash flow, rapid deleveraging, and a 0.40 PEG ratio suggest the owner of The North Face, Vans, and Timberland may finally be finding its footing.
⚛️ Quantinuum (QNT): The $1.6B Quantum Leap, Insiders Loading at $60, and the Multiverse of Single-Digit Sales
Quantinuum's blockbuster IPO and $24 million insider-buying wave highlight the enormous promise—and equally enormous risks—of quantum computing. Revolutionary science, massive losses, and moonshot ambitions make QNT one of the market's most fascinating speculative bets.
🦅 Erie Indemnity (ERIE): The Hidden Fee Castle Behind an 11-Day Short Squeeze Setup
Erie Indemnity isn't a traditional insurer. It collects fees rather than assuming most underwriting risk, creating one of the most unique business models in financial services. After a rare $1.4 million insider purchase, a 59% decline from all-time highs, and nearly 12 days-to-cover short interest, investors may want another look at this Dividend Aristocrat.
🍩 Krispy Kreme (DNUT): The 3G Mastermind, 7-Day Squeeze Trap, and the Great Post-IPO Cash Flow Resuscitation
Krispy Kreme shares remain down more than 80% from their highs, but insiders—including former 3G Capital executive Bernardo Hees—are buying aggressively. With free cash flow finally turning positive and margins improving, the iconic doughnut maker may be entering a new chapter.
🚀 Robinhood (HOOD): The $35M Insider Bet, the Great Wealth Transfer, and the Price of Fintech Dominance
Robinhood has evolved far beyond a commission-free trading app. With $307 billion in platform assets, 4.3 million Gold subscribers, and a $35 million insider purchase from fintech legend Meyer Malka, the company is increasingly positioning itself at the center of the next generation's financial lives.
🫁 Summit Therapeutics (SMMT): The Keytruda Challenger, the Insider Buying Spree, and the November FDA Showdown
Summit Therapeutics may be one of biotech's most fascinating high-risk, high-reward stories. Ivonescimab is taking aim at Keytruda, insiders keep buying shares, short interest remains elevated, and a major FDA decision looms in November 2026.